Clinical Trial Update: Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing initial dosing parameters for Zemplar (paricalcitol) in stage V chronic kidney disease patients on hemodialysis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• Zemplar (Paricalcitol)

Snippet

Sponsor: Abbott | Conditions: Kidney Failure, Chronic | Phase 4 | Status: COMPLETED